Rebecca Vasquez, MD: Ruxolitinib in Active and Stable Vitiligo

October 27, 2026

Dr. Vasquez discusses how distinguishing active from stable vitiligo can help guide treatment decisions, including the use of patient history, serial photography, and clinical signs of disease activity. She reviews how topical ruxolitinib targets JAK1/JAK2 signaling involved in vitiligo pathogenesis and highlights data demonstrating facial repigmentation in patients with both progressive and stable disease. Dr. Vasquez emphasizes that meaningful repigmentation can take time and that treatment response may vary by anatomic site and the presence of pigmented hair. She also explains that patients with longstanding stable vitiligo may still benefit from treatment, expanding therapeutic options for individuals who previously had limited choices.

Topics Covered:

Identifying active vs stable vitiligo in clinical practice
Efficacy of topical ruxolitinib across different levels of disease activity
Treatment expectations, response timelines, and factors affecting repigmentation

MORE EXPERT PERSPECTIVES IN VITILIGO

Stephanie DePouw-Simmerman, DNP, APRN: Overview and Long-Term Safety Profile of Ruxolitinib for Vitiligo

Stephanie DePouw-Simmerman, DNP, APRN, outlines the 2-year safety data for ruxolitinib in vitiligo treatment, noting that common side effects like nasopharyngitis, upper respiratory infections, and

Donna Lam Cahill, PA-C: Long-Term Body Repigmentation Data in Patients With Vitiligo

Donna Lam Cahill, PA-C, outlines the psychosocial burdens of vitiligo, emphasizing that a patient’s disease burden does not always correlate directly with the amount of

Erik Domingues, MD: Long-Term Vitiligo Management and Repigmentation

Dr. Domingues discusses his tips for managing vitiligo as a chronic autoimmune disease, emphasizing patient engagement and setting realistic expectations for repigmentation. He reviews differences

Iltefat Hamzavi, MD: The Role of JAK Inhibition in Treating Vitiligo

Iltefat Hamzavi, MD, discusses the evolving role of Janus kinase (JAK) inhibition in the treatment of vitiligo. He compares JAK inhibitors such as topical ruxolitinib

Alexa Hetzel, PA-C: Improving Vitiligo Facial Repigmentation with Topical JAK Inhibitors

Alexa Hetzel, PA-C, discusses the use of a non-steroidal topical JAK inhibitor to promote facial repigmentation in patients with vitiligo. She highlights clinical evidence demonstrating

Tristan Hasbargen, PA-C: Setting Expectations for a Long-Term Approach to Repigmentation

This review article examines vitiligo repigmentation, including treatment timelines, differences in response by body area, and long-term treatment adherence.

David Rosmarin, MD: Efficacy of Ruxolitinib Cream in Progressive and Stable Vitiligo

David Rosmarin, MD, the chair of the Department of Dermatology at Indiana University in Indianapolis, discusses results from a pooled subgroup analysis of the 104-week

Seemal Desai, MD, FAAD: Providing Effective Treatment for Patients with Facial Vitiligo

Dr. Desai discusses treatment strategies for patients with Vitiligo, focusing specifically on the use of Ruxolitinib> cream 1.5% for depigmented areas affecting the face and

Chantel Hillestad, RN, MSN, DCNP, FNP-C: Treating Patients with Vitiligo on the Hands

This review article examines the challenges of treating vitiligo on the hands, including acral repigmentation, follicular density, UV exposure, and sun protection.

Chantel Hillestad, RN, MSN, DCNP, FNP-C: Restoring Pigmentation in Patients with Vitiligo

This review article examines the use of ruxolitinib for vitiligo, including repigmentation outcomes in pediatric and adult patients.

Seemal Desai, MD, FAAD: Assessing Efficacy of Ruxolitinib in Characteristic Subgroups for Patients with Vitiligo

This original research article evaluates ruxolitinib cream 1.5% to address vitiligo, including efficacy and durable repigmentation across patient subgroups.

Jennifer Silva, APRN-DNP: Safety Considerations for Treating Patients with Vitiligo

Jennifer Silva discusses important safety considerations when treating patients with Vitiligo using JAK inhibitors, emphasizing the need for clear patient counseling regarding black box warnings

Julien Seneschal, MD, PhD: An Update on Topical and Systemic JAK Inhibition for Vitiligo

Dr. Seneschal provides an update on the evolving role of JAK inhibitors in the treatment of Vitiligo, reviewing both currently available topical therapies and investigational

Jennifer Silva, APRN-DNP: Providing Adequate Treatment for Patients with Vitiligo

Jennifer Silva, APRN-DNP, outlines treatment options for patients with vitiligo who have not responded well to traditional therapies.

Iltefat Hamzavi, MD: Combining Phototherapy with Topical Therapy in Patients with Vitiligo

This review article examines ruxolitinib cream with phototherapy for vitiligo, including extensive disease and strategies to optimize repigmentation.

David Rosmarin, MD: Updates in Topical and Systemic Vitiligo Treatment

This review article examines long-term JAK inhibitor therapy for vitiligo, including ruxolitinib cream and emerging oral JAK inhibitors.

Gina Mangin, MPAS, PA-C: Coaching Pearls for Patients with Vitiligo

This review article examines patient-centered vitiligo care, including realistic expectations, treatment adherence, motivation, and psychosocial support.

Gina Mangin, MPAS, PA-C: Using Light Box Therapy for Patients with Vitiligo

Gina Mangin, MPAS, PA-C, discusses the role of light box therapy in vitiligo management, with a focus on setting clear expectations around treatment timelines and

Nada Elbuluk, MD: Psychological Comorbidity Assessment and Counseling for Patients with Vitiligo

Nada Elbuluk, MD, discusses the importance of assessing psychological comorbidities in patients with vitiligo by gathering key social information, including daily activities, living situation, and

Shanna Miranti, MPAS, PA-C: Prescribing Ruxolitinib for Patients with Vitiligo

Shanna Miranti, MPAS, PA-C, discusses prescribing considerations for topical ruxolitinib in patients with vitiligo, emphasizing the importance of prior treatment attempts with topical corticosteroids and

James Del Rosso, DO: Discussing Early Immune Activity Upon Ruxolitinib Cream Withdrawal

Dr. Del Rosso, JCAD’s Clinical Editor-in-Chief, reviews a poster presented by Volkova et al at the 2024 American Academy of Dermatology annual meeting. The poster

JCAD Archives